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Objective: the outcomes for patients after endovascular treatment of abdominal aortic aneurysm (AAA) are determined
primarily by the endpoints of death and endoleaks, the latter representing continued risk of rupture. The data of a
multicentre registry were analysed with regard to the early outcome of stent-graft procedures for AAA and the complications
associated with this treatment. In addition, the results during follow-up were analysed by determining mortality and
endoleak development as separate endpoints and as a combined endpoint defined as endoleak-free survival.
Setting: 38 European institutions of Vascular Surgery collaborating in a multicentre registry project.
Patients and methods: 899 patients with AAA underwent between May 1994 and March 1998 elective endovascular
repair (818 men and 81 women; mean age 69 years). 80 (8.9%) of the patients had medical conditions that excluded
them from open repair. 818 (91%) of patients had a bifurcated device, 63 (7%) had a straight tube graft, and only 18
(2%) had an aorto-uni-iliac device. Clinical examination and contrast-enhanced computed tomography was performed at
fixed follow-up intervals to assess increase or decrease of the maximum transverse diameter (MTD). Endoleaks observed
at follow-up were discriminated into persistent endoleak and temporary endoleak. The latter is defined as single time
observed endoleaks or with two or more negative imaging studies between observed endoleaks. Life-table analyses were
used to calculate the rates of freedom-from-endoleak (no endoleak at any time), freedom-from-persistent endoleak
(no persistent endoleak), patient survival, and persistent-endoleak-free-survival.
Results: the median follow-up of this patient series was 6.2 months. The ratio between observed and expected follow-up
data was 82% for the overall follow-up period. However, at 18 months of follow-up this rate was only 45%. The number
of patients followed during this period was sufficient to allow statistically meaningful assessment. The MTD in patients
with temporary endoleaks demonstrated a significant decrease at 6 to 12 months compared to preoperative values (mean
57 and 53 respectively, p=0.004). In patients with persistent endoleaks there was no change between the preoperative
and 6-month MTD (mean 57 and 60 mm respectively). At 6 and 18 months freedom-from-endoleak was 83% and 74%
and freedom-from-persistent endoleak was 93% and 90%, respectively. The 18-month cumulative patient survival was
88% and the main outcome measure, the persistent endoleak-free-survival was 79%.
Conclusions: the MTD decreases in patients with temporary endoleak, but not in patients with persistent endoleak.
Therefore, the use of the rate of freedom-from-persistent endoleak, reflecting absence of persisting endoleaks to estimate
the prognosis with regard to the AAA, is justified. Determining persistent endoleak-free survival appears a rational
approach to provide a realistic outlook for patients with stent-grafted AAA. The observed 18-month endoleak-free survival
reflects a satisfactory mid-term result.
Key Words: Endovascular procedure; Abdominal aortic aneurysm; Transfemorally placed endografts; Stent-grafts;
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Introduction
Following the initial successful application of stent-
graft treatment by Parodi et al. in 1991 the short-term
efficacy of endovascular abdominal aortic aneurysm
* Presented at the Twelth Annual Meeting of the European Society (AAA) repair has been documented in a number offor Vascular Surgery, Paris, 1–4 October, 1998.
publications.1–6 However, with regard to mid- and
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long-term success much uncertainty remains. MostVascular Surgery, PO Box 1350, 5602 ZA Eindhoven, The Neth-
erlands. studies dealing with the outcome of endovascular
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Table 1. Risk factors in 899 patients with stent-graft treatment fortreatment of AAA have reported on small numbers of
AAA.patients. Usually follow-up results were not presented
SVS-ISCVS* risk scorein life-table or Kaplan–Meier format, and the outcomes
have not been assessed from the patient’s perspective.
0 1 2 3Rather, the physician’s view has been considered,
Associated diseases % of patientstaking into account primarily procedural aspects such
diabetes mellitus 71 7 2 0.2as access, graft deployment and function. The in-
smoking 54 24 14 8vestigation of device failure and the reporting of these hypertension 53 32 12 3
hyperlipidaemia 70 20 4 6events is essential to further appreciate the advantages
cardiac status 50 24 22 4and disadvantages of endovascular AAA treatment.
carotid disease 88 9 2 1.5Technical failures can perhaps be accepted if the prob- renal status 86 11 2 0.6
pulmonary status 70 18 10 2lem is resolved by a secondary endovascular inter-
vention or even by a surgical procedure. ASA physical status classification No. of patients (%)
ASA I 77 (8.6)From the patient’s perspective the possibility of
ASA II 334 (37.1)dying, either from a related or unrelated cause, is of
ASA III 408 (45.4)greatest relevance. Therefore, survival rate over time ASA IV 80 (8.9)
is the principal risk to be assessed for the patient. But
* Society of Vascular Surgery–International Society of Cardio-endoleaks are also important. If an endoleak persists,
vascular Surgery, North American Chapter.the aneurysm remains at risk of rupture. Like survival,
the absence of endoleak is a time-dependent outcome
that may best be represented in a life-table format as
notified to the EUROSTAR Data Registry Center priorrate of freedom-from-endoleak. Moreover, one may
to operation. Data on patients operated upon beforedistinguish between freedom-from-endoleak for ab-
the 1st July 1996 were retrieved from hospital notessence of any endoleak, and freedom-from-persistent
and other records retrospectively. This cohort, whichendoleak if only a persistent endoleak is the event of
consisted of 364 patients, was treated in 19 centres.interest. Considering mortality and persistent en-
Therefore, this study involved the data on a total ofdoleak as a combined endpoint, defined as “persistent-
899 patients. They were provided from 38 centres inendoleak-free survival” appears a simple and practical
different European countries. Ten of the centres hadapproach to provide a realistic prognosis to a patient
recruited less than five patients, 11 centres five to 15of what can be expected if he or she chooses to undergo
patients, 14 centres 16 to 50 patients, two centres 51this form of treatment.
to 100 patients, and one centre more than 100 patients.This report documents the results of a multicentre
Of the 899 patients 818 (91%) were men, and 81registry, organised by the “EUROSTAR” collaborators’
(9%) were women. The mean age was 69 years (rangegroup, with regard to the procedural and follow-up
37 to 90). The American Society of Anaesthesiologydata of patients treated by stent-graft techniques in
(ASA) risk classification was used to represent thea large number of European vascular institutions.7
patient’s risk profile. The distribution in the differentThe early outcome and perioperative complications
categories is represented in Table 1. Factors that mayare outlined. In addition, with regard to the follow-
have influenced the decision to perform endovascularup period, freedom-from-endoleak, freedom-from-
treatment rather than an open surgical procedure in-persistent endoleak, patient survival and persistent
cluded marked obesity in 192 patients (21%), previousendoleak-free survival rates are assessed. Because
laparotomy in 229 patients (25%), unfit to undergo anthere is considerable variation with regard to the es-
open abdominal aortic procedure in 77 (9%), and unfittimated rates of complications and endoleaks between
to tolerate general anaesthesia in 26 (3%).different institutions, this large-scale study was per-
Detailed preoperative imaging of the abdominalformed to provide a realistic appraisal of the outcome
aorta and iliac arteries by contrast-enhanced computedof endovascular AAA repair in Europe.
tomography (CT), and aortography was performed in
99% and 97% respectively. The median maximum
transverse diameter (MTD) of the aneurysms treatedMethods
was 55 mm with an interquartile range (IQR) of 48 to
60. The median infrarenal neck diameter was 22 mmThe study period extended from April 1994 to April
1998. Two periods of patient enrolment could be dis- (IQR 21 to 24), and the median neck length was of
25 mm (IQR 20 to 32). An anatomical classification hadtinguished.1 Five hundred and thirty-five patients op-
erated upon after 1st July 1996 had their procedures been described previously.7 In the study 17% of the
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patients demonstrated a type A morphology (normal- An intra-arterial DSA was scheduled at 1 month and
12 months. A duplex study was performed at the samesized aortic cuff at the bifurcation), 55% had a type B
(normal common iliac arteries), 17% type C (partial times as CT-scanning until the 12-month follow-up
visit. For this study combined use was made of findingsaneurysmal common iliac arteries), 7% type D (prox-
imal aneurysmal common iliac artery with small distal at CT, DSA and duplex assessments. If abnormalities
were observed with one modality this was the recordednormal segment) and 5% had a type E (completely
aneurysmal common iliac arteries). 97% of patients finding. The prime imaging parameters determined
preoperatively and with each follow-up visit were: (1)had symmetrical morphology, and the others had iliac
arteries of different anatomical categories at the two the maximum transverse diameter (MTD), and (2) the
presence or absence of perigraft flow in the aneurysmalsides.
Commercially manufactured devices for stent-graft sac, i.e. endoleakage. Endoleaks were distinguished as
early endoleak, that is an endoleak observed beforetreatment was used in the majority of patients in this
series, but two patients had a device implanted that discharge, and endoleaks at follow-up, that is all endo-
leaks observed at 1 month imaging studies and/or onhad been constructed by the physician.8,9 Most par-
ticipating centres were assisted during their first series subsequent follow-up studies. Endoleaks at follow-up
included residual early endoleaks that continued toof cases by a vascular surgeon or a radiologist who
had pioneered this therapeutic approach, and had exist after 1 month, and those which arose de novo.
Endoleaks were also classified by site: proximal at-extensive experience acquired with the type of device
used. Most commonly procedures were performed in tachment, midgraft level, distal attachment site, and
those originating from side-branches.the operating room using mobile fluoroscopy equip-
ment. Completion angiograms were performed to as-
sess the procedural results. Vascular surgeons and
radiologists usually worked together in teams. There
Data analysis and study endpointswere differences between centres with regard to the
use of systemic or regional heparinisation, the ap-
All data were recorded on a computerised database.plication of coil embolisation of side-branches prior
Operative technical details, such as the type of an-to stent-graft, and the preference for a unilateral or
aesthesia, and the need for adjuvant procedures werebilateral common femoral artery exploration with
recorded. In addition, information on the duration ofarteriotomy for the implantation of bifurcated devices.
the procedure, duration of fluoroscopy, duration of
intensive care unit (ICU) stay, and duration of hospital
administration were entered. Early results were rep-
resented by the mortality at one month, and the oc-Data collection and assessment
currence of systemic and local (arterial) complications.
All continuous variables were expressed as medianStandardised Case Record Forms were made available
by the EUROSTAR organisation to participating in- values and interquartile ranges.
Results after discharge were recorded in terms ofstitutions from July 1996. During the prospective study
period the informed consent registration page was late complications, and the development of endoleaks
during follow-up. Two patterns of endoleak at follow-faxed preoperatively to the Data Registry Centre. Com-
pleted forms with baseline and clinical data, sum- up were distinguished in this analysis according to
the frequency and the time period of identification:marised information on the CT and angiographic
findings, details of the stent-graft procedure, and ob- (1) persisting endoleaks, which were observed either on
at least two subsequent follow-up visits or with oneservations from the completion angiography were sent
to the Data Registry Center after discharge of the negative study in between the two positive studies,
(2) temporary endoleaks, which were all other endoleaks,patient. Subsequently, follow-up forms with clinical
and imaging data were submitted after each outpatient e.g. a single-time-observed leak, or more than one
negative study between two positive studies, i.e. re-visit. Follow-up data consisted of information on the
patient’s general condition as well as the presence or mote occurrence.
Changes in the MTD of aneurysms between theabsence of endoleaks and changes in the MTD of the
aneurysmal sac. In the case of death or conversion to preoperative measurements and imaging examina-
tions during follow-up were correlated with the oc-an open procedure details of these events were re-
corded as they occurred. currence of endoleaks at follow-up. Median values
and interquartile ranges were used to represent theseThe imaging follow-up protocol included a CT-scan
at 1, 3, 6, 12, 18 and 24 months, and yearly thereafter. values. For this correlation a paired Wilcoxon test
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Table 2. Adjuvant procedures in 899 patients with stent-graft patients (2%), and another two were subsequently
treatment for AAA. converted to open operations during the first post-
No. of procedures operative month. There were 29 early deaths (3.2%).
Of these, 20 occurred during the hospital stay, and nine
Endovascular procedures (total) 162 shortly thereafter. Causes of death included cardiacangioplasty/stent 132
coil embolisation 30 events in eight, multi-organ failure or sepsis in six,
Surgical procedures (total) 84 pulmonary failure in two, colonic ischaemia in one,
endarterectomy 14 haemorrhage in two, and cerebral complications in
iliofemoral bypass 4
three patients. The mortality rate correlated sig-crossover femorofemoral bypass 11
transposition of hypogastric artery 3 nificantly with the ASA category with 10 deaths
decoiling of iliac artery 2 (12.5%) in patients in ASA IV category, and 19 deaths
other arterial reconstruction 43
(2.3%) in patients in categories I to III (p=0.001).miscellaneous 7
Failure to complete the implantation occurred in 26
patients. The reasons included migration, inability towas used. Life-table analysis and Kaplan–Meier curves
deploy the device, inability to connect an iliac limb towere constructed to represent the freedom-from-endoleak
a main device, and graft thrombosis. In 18, conversion(no endoleak at follow-up), freedom-from-persistent en-
to an open procedure was required. In five patients adoleak (no persistent endoleak at follow-up), and patient
femorofemoral bypass was performed to bypass ansurvival. In addition, the cumulative survival and free-
inadvertently caused iliac artery occlusion, and indom-from-persistent endoleak data were combined
three the procedure was abandoned. Early non-fatalinto a persistent endoleak-free survival rate.
systemic complications occurred during hospital ad-
mission in 117 (13%) patients. The majority of these
were cardiac in origin. Device- and procedure-related
Results adverse events other than the need for conversion
to an open procedure during or after the operation
Devices and procedures occurred in 13% and access-site-related complications
in another 13% (Table 3).
Of the 899 patients, 797 received a modular bifurcation
device, 21 a uni-piece bifurcation device, 63 an aorto-
aortic straight tube stent-graft, and 18 an aorto-uni-
iliac device. In the last group the procedure included Early endoleak
a femorofemoral crossover bypass, and stent occluder
of one common iliac artery. The devices used were In 162 patients, 174 endoleaks were identified before
StentorÌ (331 patients), VanguardÌ (455 patients), discharge. Of these, 39 were at the proximal attachment
EVTÌ (38 patients), TalentÌ (63 patients), AneuRxÌ (10 site, 29 at mid-graft level, 52 at the distal site (together
patients), and physician-constructed prototype devices defined as graft-related endoleaks), and 54 consisted of
(two patients). Seven hundred and twenty-eight (81%) backbleeding from side-branches (non-graft-related).
procedures were performed under general an- Within 6 months 72 (41%) of the endoleaks had re-
aesthesia, 152 (17%) under spinal anaesthesia, and five solved spontaneously. Of the resolved endoleaks, 12
(0.6%) under local anaesthesia. In 14 patients the type were proximal, 15 mid-graft, 20 distal, and 25 side-
of anaesthesia was not indicated. The median oper- branch backbleeding. A secondary endovascular repair
ation time was 140 min (106–210); the fluoroscopy time was undertaken in 12 patients, and an open procedure
was 27 min (18–40); the length of ICU stay was 21 h in one. Six patients had endoleaks at discharge that
(18–24); and the duration of postprocedure hospital were related to failure to complete the stent-graft
stay was 7 days (5–10). In 239 patients, 246 adjuvant procedure. Three of these underwent a conversion
procedures were performed. One hundred and fifty- within 6 months, and three patients were managed
five patients had endovascular procedures and 84 conservatively. Fifty-four endoleaks persisted at 6
patients had open surgical procedures (Table 2). months, 39 (32%) were graft-related and 15 (28%) were
non-graft-related. This difference was not significant.
In 29 the course was unknown because of loss of
follow-up or because of the timing of follow-up relativeEarly complications
to this study.
Of the 39 proximal endoleaks one was dealt withIntraoperative conversion of the initial intervention
into an open surgical procedure was required in 18 by conversion to open surgery during the admission,
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Table 3. Complications during stent-graft procedures or during hospital admission in 899 patients.
No. of patients No. of complications
Systemic complications 117
cardiac 36
renal, urologic 32
pulmonary 26
stomach, hepatobiliary, pancreas, bowel 17
ARDS, sepsis 16
cerebral 10
laparotomy because of systemic complications 4
miscellaneous 25
Procedure- and device-related problems in: 121
advancing of delivery system 21
deployment of device 32
rupture of balloon 20
conversion to open procedure 18
device migration 16
introducer shear tear 9
device/limb occlusion 8
crossover bypass 4
aortic/arterial rupture of tear 3
iliac limb detachment 2
Access site/arterial complication 117
dissection, peforation, arterial damage 13
secondary bleeding, haematoma, false aneurysm 59
arterial thrombosis 20
arterial emboli, micro-emboli 10
wound infection, skin necrosis, lymphocoeles 13
limb loss 1
miscellaneous 16
Table 4. Numbers of registered and expected data at different follow-up periods.
Follow-up (months) Observed Expected Ratio
no. of patients no. of patients observed/expected
Predischarge 865 882 98%*
1 713 845 84%
3 623 745 84%
6 500 636 79%
12 289 410 70%
18 129 283 45%
Total 3118 3801 82%
*Corrected for deaths during admission. 2% difference due to surviving patients with early conversion.
three by open repair at a later admission, four by visits, corrected for interval deaths was 82%. However,
after 1 year there was a marked drop in this ratio tolate endovascular repairs, and 12 endoleaks closed
45% at 18 months.spontaneously. Fifteen proximal endoleaks (38%, 15/
Adverse systemic events were observed after the39), and 39 endoleaks at other sites (29%, 39/135)
first postoperative month in 3 to 4% of patients inwere still present after 6 months, rates that were not
every 3 months’ follow-up period. These complicationssignificantly different.
included a wide range of conditions, usually not re-
lated to the procedure. Cardiovascular disease con-
stituted 21 to 32% of events in each observationComplications at follow-up
interval. Procedure or device-related complications
The median follow-up period at the time of data occurred in 5 to 9% (Table 5). In six patients (0.7%)
analysis was 6.2 months (range 0 to 48). This is in- the aneurysm ruptured during follow-up. In two of
dicative of a high rate of patient recruitment during these the existence of an endoleak had been dem-
the most recent part of the study period. The com- onstrated prior to rupture and one had a stent-graft
pleteness of follow-up information is shown in Table infection. Further interventions for procedure and de-
vice-related complications were required during the4. The overall ratio of observed to expected follow-up
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Table 5. Procedure and device-related complications and interventions during the first 18 months of follow-up.
Observation period (months) 1 3 6 12 18
Number of patients followed in interval 713 622 500 289 128
Number (%) of patients with complication 50 (7) 53 (9) 46 (9) 30 (10) 12 (14)
Number of procedure/device related complications
graft migration 2 2 9 5 2
graft stenosis 5 5 6 2 1
graft thrombosis 7 9 5 6 1
leakage into sac* 28 22 17 10 5
rupture of aneurysm 1 1 2 1 1
further transfemoral intervention 15 13 15 14 8
further transabdominal intervention 3 3 3 4 3
further extra-anatomical intervention 1 5 1 2 1
Interventions for endoleak/total interventions 12/19 12/21 16/19 13/20 11/12
* Endoleaks noted by observers as a clinically significant complication. Endoleak may be recorded during more than one interval. These
figures do not equal numbers of new endoleaks in Table 6, which were based on serial imaging.
Table 6. Endoleaks at follow-up identified at different follow-up intervals.
Observation period (months) 1 3 6 12 18
Number of patients followed per interval 713 622 500 289 128
Number of patients (%) with new endoleak 57 (8) 32 (5) 17 (3) 13 (4) 2 (2)
Number of endoleaks and sites
proximal attachment 18 3 3 — —
graft 9 5 4 5 1
distal attachment 23 7 4 8 1
re-injection from side-branch 14 17 8 — —
(patients with combination of endoleaks) (7) — (2) — —
subsequent follow-up in 3 to 4.7% of the patients in based on the occurrence of persistent endoleaks only,
was 90% (s.e. 2%) at 18 months of follow-up (Fig. 1).each 3-month follow-up interval. Most of the in-
terventions were by a transfemoral approach.
Aneurysm shrinkage
The median maximum transverse diameter (MTD) ofEndoleak at follow-up
the aneurysms in the overall group decreased sig-
nificantly from a median preoperative value of 55 mmEndoleaks at follow-up developed in 1–5% in each
(48–60) to 50 mm (42–58) at 6 to 12 months post-3-month follow-up interval (Table 6). Proximal endo-
operatively (p=0.0001). In patients who never had anleaks were relatively frequent during early follow-up,
endoleak, there was a significant difference betweenbut were not observed after the sixth postoperative
the preoperative and 6- to 12-month values, 55 mmmonth. In contrast, endoleaks originating from the
(48–60) and 49 mm (42–56) respectively (p=0.0001). Ingraft itself and distal endoleaks were noted throughout
contrast, patients with persisting endoleaks had nothe follow-up period up to 18 months postoperatively.
decrease of the median MTD, preoperatively 57 mmNew endoleaks from lumbar arteries did not develop
(50–65), and after 6–12 months 60 mm (54–63). Patientsafter 6 months. A total of 64 reinterventions (53 trans-
with temporary endoleaks demonstrated a significantfemoral, 10 transabdominal and one crossover bypass
drop in MTD, from 57 mm (54–63) to 53 mm (48–53)combined with an endovascular procedure) were per-
(p=0.004).formed for endoleaks. Of these reinterventions were
successful in resolving the endoleak.
The freedom-from-endoleak rate, representing the Survival and persistent endoleak-free survival
absence of an endoleak at any time during follow-up,
was 74% (s.e. 3%) at 18 months postoperatively. The Sixty patients died in the two years following the
stent-graft procedure. In only two patients was rupturefreedom-from-persistent endoleak rate, which was
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Fig. 1. Kaplan–Meier curve for freedom-from-endoleak and freedom-from-persistent endoleak.
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Fig. 2. Kaplan–Meier curve for patient survival and persistent endoleak-free survival.
the registry after 1st July 1996, it was requested thatof the aneurysm the cause of death. The cumulative
they did not submit data on patients included insurvival rate at 18 months was 88% (s.e. 2%). The
their learning curve experience. Whilst differences inpersistent endoleak-free survival, based on the com-
treatment outcome may be influenced by the timebined patient survival and freedom-from-persistent
period within the study that the operation took place,endoleak data was 79% (s.e. 2%) at 18 months (Fig.
and experience of the team, this was not the subject2).
of the present study. The main objective was to make
a realistic assessment of results obtained from endo-
vascular aneurysm repair in Europe today. The range
Discussion of devices used represented all available stent-grafts
during the study period. The predominance (89%) of
This series represents the collective experience of 38 modular bifurcated grafts used was a reflection of the
groups in European centres with stent-graft repair of important role played by European physicians in the
AAA. Centres that were involved from the beginning development and early application of this type of
of the registry had enrolled patients in the retrospective device.10,11 Data collection in this large multicentre
part of the study, and this included their early ex- series was a laborious operation. The ratio between
observed and expected data was acceptableperience with this technique. For centres that joined
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up to 12 months after operation, but declined to a early endoleaks were still present after 6 months,
without much difference between graft-related anddisappointing 40% at 18 months. Nevertheless, a mean-
ingful analysis is possible. non-graft-related endoleaks. Proximal endoleaks per-
sisted just as frequently (38%, 15/39) as other endo-A rational indication for the treatment of an AAA,
either by open or by endovascular surgery, may be leaks (29%, 39/135) until the sixth postoperative
month. This finding corresponded with the ob-based on the premise that the mortality of treatment
is less than the risk of rupture within one year.12 The servations of Matsumura and Moore, who found no
difference in the tendency of spontaneous closureearly mortality of endovascular AAA-repair in recent
studies varied from 0–6.6%.6–8,10–14 The few studies between proximal and other endoleaks.21 Endoleaks
were associated with device migration, graft throm-comparing patients treated with stent-grafts, with a
contemporary group of controls treated by open sur- bosis, deployment problems or failure to connect the
second iliac limb (inability to complete the procedure)gery, showed no difference in mortality.15,16 Our find-
ings included an overall operative mortality in 899 in 4% of patients (6/162). The availability of adjunct
device components, such as an extra short aortic cuffpatients of 3.2%, and was significantly related to ad-
vanced co-morbidity. For ASA IV patients it was 12.8%. to seal the proximal attachment is essential.
Successful AAA exclusion results in a marked de-Parodi’s series, consisting of patients with contra-
indications for open surgery, had a mortality of 8%.17 crease in aneurysm size. The presence of endoleaks,
on the other hand, may be associated with furtherIt is to be expected that in series with predominantly
low-risk patients the observed mortality will be sub- expansion of the aneurysm, and possibly rupture.22–26
Proposals for the classification of endoleaks have beenstantially lower. It follows that a meaningful com-
parison of open and endovascular AAA-repair should made by White et al.19,20 These authors distinguished
primary endoleaks, existing from the initial procedure,preferably be made on the basis of a randomised study
in which selection bias is accounted for. Until such a and secondary or late endoleaks, which develop de
novo during follow-up. We found it difficult to followstudy is completed choice of treatment must be based
on personal preferences and economic factors. A lower precisely this classification, as it was impractical in a
life-table analysis to distinguish residual proceduralincidence of systemic complications, a shorter duration
of hospital stay, and a more rapid recovery favour the endoleaks from endoleaks that develop after the peri-
operative period. Therefore endoleaks at follow-up, asendovascular procedure. But these advantages have
to be contrasted with the expense of the stent-graft defined for the purpose of this study, included all
endoleaks observed at 1 month or thereafter. Otherand the necessity for long-term follow-up by imaging
techniques because of the risk of late endoleak de- aspects of White’s originally suggested definitions
were applied in detail. We found that endoleaks ori-velopment.
Systemic complications were observed in the post- ginating from the graft and distal attachment sites
continued to occur after 6 months of follow-up,operative period in 13%, cardiac, pulmonary, and renal
dysfunction being most frequently encountered. This whereas new proximal attachment-site endoleaks and
reinjection from side-branches were not observed afterincidence is almost identical with the 14 to 17% as
reported by Brewster and May, but higher than the this period.
Criteria for success have been outlined by the Ad5% observed by Mialhe et al.10,15,16 In comparison, the
incidence of cardiac and pulmonary complications was Hoc Committee for Standardised Reporting Practices
in Vascular Surgery of the Society for Vascular Sur-considerably lower in the present study than in a series
of open operation reported in the Canadian Aneurysm gery/International Society for Cardiovascular Sur-
gery.27 This committee distinguished between technicalStudy (4% vs. 15%, and 3% vs. 8%, respectively).18 This
is in agreement with the observations of Brewster et success and clinical success for early postoperative
results, and continuing success for late results. Theseal., who found, in a comparative study, a lower in-
cidence of systemic complications in the stent-graft- definitions each encompass a range of variables in-
cluding graft thrombosis, migration, infection and di-treated group.16
Initial exclusion of the aneurysm was achieved in lation at or adjacent to the aneurysm as endpoints. In
our view this approach will remain the basis for a82% of this series (737/899). An 18% incidence of early
endoleaks is in the middle of the reported range which methodological analysis of treatment results of endo-
vascular AAA-repair. However, a patient-oriented ana-varies from 12–44%.5,10,11,14,17,19 The majority (69%, 120/
174) of early endoleaks were graft-related, which in- lysis as presented in the present report seems justified.
The expected short- and long-term survival rate is thecludes ineffective seal at the attachment sites and leak
from the graft itself.20 Thirty-one percent (54/174) of first and most important information required by the
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the second most important variable from the patient’s Hospital; Trondheim, Norway; Ulm, Germany;
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ure of outcome. Additional risks of treatment,
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